This trial will test whether PDR001, in combination with either trametinib or dabrafenib, can safely and effectively treat thyroid cancer.
1 Primary · 0 Secondary · Reporting Duration: 1 year
Experimental Treatment
30 Total Participants · 2 Treatment Groups
Primary Treatment: PDR001 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: